Jones David Scott 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 5, 2024
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-02$11.47/sh+209$2,397→ 38,171 total - Sale
Common Stock
2024-02-02$28.49/sh−209$5,954→ 37,962 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-02−209→ 4,375 totalExercise: $11.47Exp: 2031-11-01→ Common Stock (209 underlying)
Footnotes (1)
- [F1]The option to purchase vests and becomes exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.